Here, the investigators will develop a clinicopathomic assay from biomarkers obtained from digital pathologies of resected whole-mount oral cavity and oropharyngeal squamous cell carcinoma (OCSCC and OPSCC) specimens with the goal of administering personalized novel image-guided therapies immediately after primary surgical management in OCSCC and OPSCC patients. The primary aim is to determine the association between clinicopathomic biomarkers and LRR. The secondary aim is to develop a clinicopathomic risk score (assay) such that a decision-support tool can be used by physicians for measuring the benefit of additional therapies (i.e. conventional chemotherapy +/- radiation or administering dose-escalated chemoradiation) in the adjuvant setting to reduce LRR rates.
The proposed study is significant for developing personalized treatments. The proposed research will yield high rewards to patients by providing additional information to clinicians for better prognostication and potentially adapting adjuvant treatments to improve the survival of patients with OCSCC or OPSCC.
Study Type
OBSERVATIONAL
Enrollment
450
This is a non-interventional study.
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Time to locoregional recurrence
Evaluating the time until a recurrence event has occurred in the oral cavity or oropharyngeal region
Time frame: Up to 60 months
Time to distant metastasis
Evaluating onset of distant metastasis
Time frame: Up to 60 months
Time to death
Evaluating time to cancer-related death
Time frame: Up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.